Unique pharmacologic properties of amlodipine
Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. Pharmacokinetic studies in animal models demonstrate a more prolonged half-life,...
Gespeichert in:
Veröffentlicht in: | The American journal of cardiology 1994-01, Vol.73 (3), p.A2-A9 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | A9 |
---|---|
container_issue | 3 |
container_start_page | A2 |
container_title | The American journal of cardiology |
container_volume | 73 |
creator | Burges, Roger Moisey, Donna |
description | Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. Pharmacokinetic studies in animal models demonstrate a more prolonged half-life, high volume of distribution, and gradual elimination of amlodipine compared with that of other calcium antagonists. The presence of a basic side chain at the 2-position of the dihydropyridine ring renders the molecule > 90% ionized at physiologic pH and is believed to be primarily responsible for its markedly different pharmacologic and pharmacokinetic properties. Amlodipine has slow receptor binding kinetics that result in a gradual onset of action and may allow for less dependence on instantaneous plasma levels. Although amlodipine appears to bind to additional calcium channel recognition sites blocked by diltiazem and verapamil, it does not significantly depress heart rate nor does it produce significant negative inotropic effects or electrophysiologic disturbances. Preclinical studies indicate that amlodipine is a potent antihypertensive agent with natriuretic and diuretic properties that may enhance its ability to reduce blood pressure without attendant fluid retention. |
doi_str_mv | 10.1016/0002-9149(94)90268-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76352297</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0002914994902682</els_id><sourcerecordid>7187624</sourcerecordid><originalsourceid>FETCH-LOGICAL-c299t-b5aa54eda0add5cad0a9a4adf079ab86680498bafd1ea64352273b82e30815f63</originalsourceid><addsrcrecordid>eNp9kE1LAzEQhoMotVb_gULxIHpYTbK72eQiSPELCl7sOcwms5qyu1mTVvDfm9riwYOnMMzzTl4eQk4ZvWaUiRtKKc8UK9SlKq4U5UJmfI-MmaxUxhTL98n4FzkkRzEu08hYKUZkJHNGVcXHJFv07mON0-EdQgfGt_7NmekQ_IBh5TBOfTOFrvXWDa7HY3LQQBvxZPdOyOLh_nX2lM1fHp9nd_PMcKVWWV0ClAVaoGBtacBSUFCAbWiloJZCSFooWUNjGYIo8pLzKq8lx5xKVjYin5CL7d1UJLWLK925aLBtoUe_jroSm4yqEnj-B1z6dehTN81zmgspKpmgYguZ4GMM2OghuA7Cl2ZUb1TqjSe98aRVoX9UpviEnO1ur-sO7W9o5y7tb7d7TCY-HQYdjcPeoHUBzUpb7_7_4BuEd4G-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230368678</pqid></control><display><type>article</type><title>Unique pharmacologic properties of amlodipine</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Burges, Roger ; Moisey, Donna</creator><creatorcontrib>Burges, Roger ; Moisey, Donna</creatorcontrib><description>Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. Pharmacokinetic studies in animal models demonstrate a more prolonged half-life, high volume of distribution, and gradual elimination of amlodipine compared with that of other calcium antagonists. The presence of a basic side chain at the 2-position of the dihydropyridine ring renders the molecule > 90% ionized at physiologic pH and is believed to be primarily responsible for its markedly different pharmacologic and pharmacokinetic properties. Amlodipine has slow receptor binding kinetics that result in a gradual onset of action and may allow for less dependence on instantaneous plasma levels. Although amlodipine appears to bind to additional calcium channel recognition sites blocked by diltiazem and verapamil, it does not significantly depress heart rate nor does it produce significant negative inotropic effects or electrophysiologic disturbances. Preclinical studies indicate that amlodipine is a potent antihypertensive agent with natriuretic and diuretic properties that may enhance its ability to reduce blood pressure without attendant fluid retention.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/0002-9149(94)90268-2</identifier><identifier>PMID: 8310972</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Amlodipine - chemistry ; Amlodipine - pharmacokinetics ; Amlodipine - pharmacology ; Animals ; Aorta - drug effects ; Calcium ; Calcium Channel Blockers - pharmacology ; Delayed-Action Preparations ; Dogs ; Drugs ; Hypertension - drug therapy ; In Vitro Techniques ; Kidney - drug effects ; Muscle Contraction - drug effects ; Myocardial Reperfusion Injury - prevention & control ; Nifedipine - pharmacology ; Pharmacology ; Portal Vein - drug effects ; Rats ; Rats, Inbred SHR ; Rats, Inbred WKY ; Vascular Resistance</subject><ispartof>The American journal of cardiology, 1994-01, Vol.73 (3), p.A2-A9</ispartof><rights>1993</rights><rights>Copyright Elsevier Sequoia S.A. Jan 27, 1994</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c299t-b5aa54eda0add5cad0a9a4adf079ab86680498bafd1ea64352273b82e30815f63</citedby><cites>FETCH-LOGICAL-c299t-b5aa54eda0add5cad0a9a4adf079ab86680498bafd1ea64352273b82e30815f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0002-9149(94)90268-2$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8310972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Burges, Roger</creatorcontrib><creatorcontrib>Moisey, Donna</creatorcontrib><title>Unique pharmacologic properties of amlodipine</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. Pharmacokinetic studies in animal models demonstrate a more prolonged half-life, high volume of distribution, and gradual elimination of amlodipine compared with that of other calcium antagonists. The presence of a basic side chain at the 2-position of the dihydropyridine ring renders the molecule > 90% ionized at physiologic pH and is believed to be primarily responsible for its markedly different pharmacologic and pharmacokinetic properties. Amlodipine has slow receptor binding kinetics that result in a gradual onset of action and may allow for less dependence on instantaneous plasma levels. Although amlodipine appears to bind to additional calcium channel recognition sites blocked by diltiazem and verapamil, it does not significantly depress heart rate nor does it produce significant negative inotropic effects or electrophysiologic disturbances. Preclinical studies indicate that amlodipine is a potent antihypertensive agent with natriuretic and diuretic properties that may enhance its ability to reduce blood pressure without attendant fluid retention.</description><subject>Amlodipine - chemistry</subject><subject>Amlodipine - pharmacokinetics</subject><subject>Amlodipine - pharmacology</subject><subject>Animals</subject><subject>Aorta - drug effects</subject><subject>Calcium</subject><subject>Calcium Channel Blockers - pharmacology</subject><subject>Delayed-Action Preparations</subject><subject>Dogs</subject><subject>Drugs</subject><subject>Hypertension - drug therapy</subject><subject>In Vitro Techniques</subject><subject>Kidney - drug effects</subject><subject>Muscle Contraction - drug effects</subject><subject>Myocardial Reperfusion Injury - prevention & control</subject><subject>Nifedipine - pharmacology</subject><subject>Pharmacology</subject><subject>Portal Vein - drug effects</subject><subject>Rats</subject><subject>Rats, Inbred SHR</subject><subject>Rats, Inbred WKY</subject><subject>Vascular Resistance</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1LAzEQhoMotVb_gULxIHpYTbK72eQiSPELCl7sOcwms5qyu1mTVvDfm9riwYOnMMzzTl4eQk4ZvWaUiRtKKc8UK9SlKq4U5UJmfI-MmaxUxhTL98n4FzkkRzEu08hYKUZkJHNGVcXHJFv07mON0-EdQgfGt_7NmekQ_IBh5TBOfTOFrvXWDa7HY3LQQBvxZPdOyOLh_nX2lM1fHp9nd_PMcKVWWV0ClAVaoGBtacBSUFCAbWiloJZCSFooWUNjGYIo8pLzKq8lx5xKVjYin5CL7d1UJLWLK925aLBtoUe_jroSm4yqEnj-B1z6dehTN81zmgspKpmgYguZ4GMM2OghuA7Cl2ZUb1TqjSe98aRVoX9UpviEnO1ur-sO7W9o5y7tb7d7TCY-HQYdjcPeoHUBzUpb7_7_4BuEd4G-</recordid><startdate>19940127</startdate><enddate>19940127</enddate><creator>Burges, Roger</creator><creator>Moisey, Donna</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19940127</creationdate><title>Unique pharmacologic properties of amlodipine</title><author>Burges, Roger ; Moisey, Donna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c299t-b5aa54eda0add5cad0a9a4adf079ab86680498bafd1ea64352273b82e30815f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Amlodipine - chemistry</topic><topic>Amlodipine - pharmacokinetics</topic><topic>Amlodipine - pharmacology</topic><topic>Animals</topic><topic>Aorta - drug effects</topic><topic>Calcium</topic><topic>Calcium Channel Blockers - pharmacology</topic><topic>Delayed-Action Preparations</topic><topic>Dogs</topic><topic>Drugs</topic><topic>Hypertension - drug therapy</topic><topic>In Vitro Techniques</topic><topic>Kidney - drug effects</topic><topic>Muscle Contraction - drug effects</topic><topic>Myocardial Reperfusion Injury - prevention & control</topic><topic>Nifedipine - pharmacology</topic><topic>Pharmacology</topic><topic>Portal Vein - drug effects</topic><topic>Rats</topic><topic>Rats, Inbred SHR</topic><topic>Rats, Inbred WKY</topic><topic>Vascular Resistance</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Burges, Roger</creatorcontrib><creatorcontrib>Moisey, Donna</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Burges, Roger</au><au>Moisey, Donna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Unique pharmacologic properties of amlodipine</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>1994-01-27</date><risdate>1994</risdate><volume>73</volume><issue>3</issue><spage>A2</spage><epage>A9</epage><pages>A2-A9</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Amlodipine is an intrinsically long-acting, vasoselective calcium antagonist structurally related to nifedipine, but with unique binding and pharmacologic properties that distinguish it from other agents of this class. Pharmacokinetic studies in animal models demonstrate a more prolonged half-life, high volume of distribution, and gradual elimination of amlodipine compared with that of other calcium antagonists. The presence of a basic side chain at the 2-position of the dihydropyridine ring renders the molecule > 90% ionized at physiologic pH and is believed to be primarily responsible for its markedly different pharmacologic and pharmacokinetic properties. Amlodipine has slow receptor binding kinetics that result in a gradual onset of action and may allow for less dependence on instantaneous plasma levels. Although amlodipine appears to bind to additional calcium channel recognition sites blocked by diltiazem and verapamil, it does not significantly depress heart rate nor does it produce significant negative inotropic effects or electrophysiologic disturbances. Preclinical studies indicate that amlodipine is a potent antihypertensive agent with natriuretic and diuretic properties that may enhance its ability to reduce blood pressure without attendant fluid retention.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>8310972</pmid><doi>10.1016/0002-9149(94)90268-2</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9149 |
ispartof | The American journal of cardiology, 1994-01, Vol.73 (3), p.A2-A9 |
issn | 0002-9149 1879-1913 |
language | eng |
recordid | cdi_proquest_miscellaneous_76352297 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Amlodipine - chemistry Amlodipine - pharmacokinetics Amlodipine - pharmacology Animals Aorta - drug effects Calcium Calcium Channel Blockers - pharmacology Delayed-Action Preparations Dogs Drugs Hypertension - drug therapy In Vitro Techniques Kidney - drug effects Muscle Contraction - drug effects Myocardial Reperfusion Injury - prevention & control Nifedipine - pharmacology Pharmacology Portal Vein - drug effects Rats Rats, Inbred SHR Rats, Inbred WKY Vascular Resistance |
title | Unique pharmacologic properties of amlodipine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T20%3A37%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Unique%20pharmacologic%20properties%20of%20amlodipine&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Burges,%20Roger&rft.date=1994-01-27&rft.volume=73&rft.issue=3&rft.spage=A2&rft.epage=A9&rft.pages=A2-A9&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/0002-9149(94)90268-2&rft_dat=%3Cproquest_cross%3E7187624%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230368678&rft_id=info:pmid/8310972&rft_els_id=0002914994902682&rfr_iscdi=true |